EDIT
Editas Medicine, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Editas Medicine has 3 disclosed suppliers and 8 disclosed customers in SEC filings.
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
SentencePursuant to the Cas9-I License Agreement, Harvard and Broad granted us an exclusive, worldwide, royalty-bearing, sublicensable license to the Harvard/Broad Cas9-I Patent Rights to make, have made, use, sell, offer for sale, have sold, import, and export products and services in the field of the prevention and treatment of human disease, subject to certain limitations and retained rights.
EDIT 10-Kaccession 0001650664-26-000017
SentenceFor example, certain patent applications licensed to us by Broad are co-owned with NIH.
EDIT 10-Kaccession 0001650664-26-000017
SentenceThe March 2017 amendment to the Cas9-I License Agreement included a license to Rockefeller's rights in such patents and patent applications.
EDIT 10-Kaccession 0001650664-26-000017
Sentencethe cost to obtain licenses to intellectual property, such as those with Harvard University, or Harvard, The Broad Institute, Inc., or Broad Institute, Editas Medicine, Inc., or Editas, and Bio Palette Co., Ltd., or Bio Palette, and related future payments should certain success, development and regulatory milestones be achieved;
SentenceIn connection with our collaboration with BMS, we have received an aggregate of $159.0 million in payments, which have primarily consisted of the initial upfront and amendment payments, development milestone payments, research funding support, and certain opt-in fees.
SentenceIn addition, in December 2023, we and Vertex Pharmaceuticals Incorporated ("Vertex") entered into a license agreement (the "Vertex License Agreement"), under which Vertex obtained a non-exclusive license for our Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of SCD and TDT, including Vertex's CASGEVY TM (exagamglogene autotemcel).
SentenceWe have primarily financed our operations through various equity financings, payments received under our research collaboration with BMS, our former strategic alliance with Allergan Pharmaceuticals International Limited (together with its affiliates, "Allergan"), which was terminated in August 2020, payments received under the DRI Agreement in connection with the Vertex License Agreement, and payments under the Vertex License Agreement.
EDIT 10-Kaccession 0001650664-26-000017
SentenceWe have financed our operations primarily through public offerings of our common stock, our research collaboration with Bristol Myers Squibb Company ("BMS") through its wholly owned subsidiary, Juno Therapeutics, Inc. , payments under our former strategic alliance with Allergan Pharmaceuticals International Limited (together with its affiliates, "Allergan"), which was terminated in August 2020, payments received under our purchase and sale agreement with DRI Healthcare Acquisitions LP, and payments under our license agreement with Vertex Pharmaceuticals, Incorporated ("Vertex").
EDIT 10-Kaccession 0001650664-26-000017
SentenceIn October 2024, we entered into an agreement (the "DRI Agreement") with a wholly owned subsidiary of DRI Healthcare Trust ("DRI") providing for an upfront cash payment by DRI to us of $57.0 million.
EDIT 10-Kaccession 0001650664-26-000017
SentenceWe are also party to a non-exclusive collaboration and licensing agreement with Immatics to combine gamma-delta T cell adoptive cell therapies and gene editing for the treatment of cancer.
EDIT 10-Kaccession 0001650664-26-000017
SentenceIn May 2015, we entered into a collaboration and license agreement with Juno Therapeutics, a subsidiary of BMS, for the research and development of engineered T cells with CARs and eTCRs that have been genetically modified to recognize and kill other cells.
EDIT 10-Kaccession 0001650664-26-000017
+5.45%
vs ±18.5% implied · ×0.29
shaded = implied · ▲▼ = realized
Editas Medicine, Inc.
2.62
Linked news
Expected move
Inputs8Q avg ±10.4%·×0.97·fair
straddle ±16.7%
spot 2.67exp Nov 20ATM strike 2.5ATM straddle 0.53IV 102%